Kriya Announces Publication of Preclinical Data for its Investigational AAV-FGF21 Gene Therapy Demonstrating Durable Reversal of Liver Fibrosis
13 nov. 2024 16h30 HE
|
Kriya Therapeutics, Inc.
– Results demonstrate statistically significant fibrosis reversal and protection against hepatocellular carcinoma in animal models of MASH – – Kriya plans to evaluate KRIYA-497, a one-time...
Kriya Highlights Positive Preclinical Data for KRIYA-586, a Gene Therapy Product Candidate for Thyroid Eye Disease (TED), at ESOPRS Annual Meeting
12 sept. 2024 09h05 HE
|
Kriya Therapeutics, Inc.
– Preclinical data demonstrate pharmacodynamic activity of KRIYA-586, an investigational gene therapy which encodes for an anti-IGF1R antibody – – Kriya anticipates advancing KRIYA-586 into the...
Kriya Appoints Scientific Co-Founder J. Fraser Wright, Ph.D., as Chief Gene Therapy Officer
08 juil. 2024 09h05 HE
|
Kriya Therapeutics, Inc.
– Dr. Wright has three decades of experience in the research and development of viral vectors and has been involved in the development of multiple approved gene therapies globally – PALO ALTO, Calif....
Kriya Appoints Katherine Eade as Chief Legal Officer
18 juin 2024 09h05 HE
|
Kriya Therapeutics, Inc.
PALO ALTO, Calif., and RESEARCH TRIANGLE PARK, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies to address common...
Kriya Announces Three Presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
02 mai 2024 09h05 HE
|
Kriya Therapeutics, Inc.
– Kriya is developing KRIYA-825 as a potential one-time gene therapy expressing a fusion protein inhibiting the activity of complement C3 and C5 for the treatment of Geographic Atrophy – PALO...
Kriya Announces Six Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2024
22 avr. 2024 16h30 HE
|
Kriya Therapeutics, Inc.
– Current pipeline of gene therapies for common diseases spans three major therapeutics areas: ophthalmology, metabolic disease and neurology – – Company to host symposium on “Advancing Gene...
Kriya Provides Update on Pipeline Progress Ahead of Company Presentation at 42nd Annual J.P. Morgan Healthcare Conference
08 janv. 2024 09h00 HE
|
Kriya Therapeutics, Inc.
– Kriya anticipates up to 5 programs to enter clinic by the end of 2025 – – Current pipeline of gene therapies for common diseases spans three major therapeutics areas: ophthalmology, metabolic...
Kriya Announces Gene Therapy Program for Thyroid Eye Disease
05 janv. 2024 09h00 HE
|
Kriya Therapeutics, Inc.
– KRIYA-586 is designed to be a one-time treatment delivered by focal peribulbar injection, that encodes an antibody blocking the Insulin-Like Growth Factor 1 Receptor (IGF-1R), a clinically validated...
Kriya to Present at the J.P. Morgan 42nd Annual Healthcare Conference
20 déc. 2023 08h30 HE
|
Kriya Therapeutics, Inc.
PALO ALTO, Calif., and RESEARCH TRIANGLE PARK, N.C., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies to address common...
Kriya Announces Exclusive License and Collaboration Agreement with Everads to Advance Gene Therapies for Prevalent Diseases in Ophthalmology Including Geographic Atrophy
27 sept. 2023 08h30 HE
|
Kriya Therapeutics, Inc.
– Everads' next generation suprachoroidal delivery technology enables targeted drug delivery to the retina, which Kriya intends to use for multiple ophthalmology gene therapy product candidates – ...